Biodesix, Inc. (NASDAQ:BDSX) Insider Gary Anthony Pestano Sells 16,748 Shares

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) insider Gary Anthony Pestano sold 16,748 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $15,408.16. Following the sale, the insider now owns 156,008 shares of the company's stock, valued at $143,527.36. The trade was a 9.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Biodesix Price Performance

NASDAQ BDSX traded up $0.02 on Friday, hitting $0.99. 199,585 shares of the company's stock were exchanged, compared to its average volume of 496,630. The stock has a 50-day moving average of $1.23 and a 200-day moving average of $1.48. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a 52 week low of $0.86 and a 52 week high of $2.04. The stock has a market cap of $143.28 million, a price-to-earnings ratio of -2.53 and a beta of 1.06.

Institutional Investors Weigh In On Biodesix

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC lifted its stake in Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company's stock worth $41,000 after purchasing an additional 21,179 shares during the last quarter. Boothbay Fund Management LLC bought a new position in shares of Biodesix in the 4th quarter valued at $52,000. MYDA Advisors LLC bought a new position in shares of Biodesix in the 4th quarter valued at $76,000. Jane Street Group LLC bought a new position in shares of Biodesix in the 4th quarter valued at $119,000. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Biodesix in the 3rd quarter valued at $262,000. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.